RT Journal Article
SR Electronic
T1 SARS-CoV-2 viral replication persists in the human lung for several weeks after onset of symptomatic severe COVID-19 and is associated with attenuated pulmonary immunity and variant-specific clinical sequalae
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.06.23286834
DO 10.1101/2023.03.06.23286834
A1 Tomasicchio, M
A1 Jaumdally, S
A1 Pooran, A
A1 Esmail, A
A1 Wilson, L
A1 Kotze, A
A1 Semple, L
A1 Meier, S
A1 Pillay, K
A1 Roberts, R
A1 Kriel, R
A1 Meldau, R
A1 Oelofse, S
A1 Mandviwala, C
A1 Burns, J
A1 Londt, R
A1 Davids, M
A1 van der Merwe, C
A1 Roomaney, A
A1 Kühn, L
A1 Perumal, T
A1 Scott, A.J
A1 Hale, M.J
A1 Baillie, V
A1 Mahtab, S
A1 Williamson, C
A1 Joseph, R
A1 Sigal, A
A1 Joubert, I
A1 Piercy, J
A1 Thomson, D
A1 Fredericks, DL
A1 Miller, MGA
A1 Nunes, M
A1 Madhi, S.A
A1 Dheda, K
YR 2023
UL http://medrxiv.org/content/early/2023/03/07/2023.03.06.23286834.abstract
AB The immunopathogenesis of severe COVID-19 is incompletely understood. In contradistinction to the upper respiratory tract where replicating (culturable) SARS-CoV-2 is recoverable approximately ∼ 4 to 8 days after symptom onset, there is paucity of data about the frequency or duration of replicating virus in the lower respiratory tract (the human lung). We undertook lung tissue sampling (needle biopsy), within ∼2 hours of death, in 42 mechanically ventilated decedents during the Beta and Delta waves. Lung biopsy cores underwent viral culture, histopathological analysis, electron microscopy, transcriptomic profiling, immunohistochemistry and cell-based flow cytometry of deconstructed tissue. 38% (16/42) of patients had culturable virus in the lung (persisting for up to 4 weeks after symptom onset). This, hitherto, undescribed bio-phenotype of lung-specific persisting viral replication was associated with an enhanced pulmonary pro-inflammatory response and variant-specific increased rates of bacterial bronchopneumonia and accelerated death. These findings question existing paradigms and suggest that in a subset of patients, concurrent, rather than sequential active viral replication continues to drive a heightened pro-inflammatory response. Our findings have potential implications for the design of therapeutic interventional strategies and clinical management of severe COVID-19 disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Bill & Melinda Gates Foundation (grant number INV-017282) and the South African Medical Research Council (grant number SHIP NCD 96756) with partial support from the Department of Science and Technology and National Research Foundation: South African Research Chair Initiative in Vaccine Preventable Diseases. The KD lab acknowledges funding from the SA MRC (RFA-EMU-02-2017), EDCTP (TMA-2015SF-1043, TMA-1051-TESAIII, TMA-CDF2015), UK Medical Research Council (MR/S03563X/1), NIH (CRDF-OISE-16-62105) and the Wellcome Trust (MR/S027777/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Human Research Ethics Committee (HREC) of the University of Cape Town (HREC approval number 866/2020) and University of Witwatersrand (HREC approval number M200313). Biosafety approvals were obtained from the Faculty Biosafety Committee of the University of Cape Town (IBC008-2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual participant data will be made available to researchers who provide a protocol that is approved by their respective human research ethics committee. All protocols will be reviewed and approved by the MITS consortium trial steering committee up to five years following publication. A data sharing agreement (DTA) will need to be concluded between the representatives of the requesting institution and the University of Cape Town Lung Institute. Data sharing requests should be directed to keertan.dheda{at}uct.ac.za